Ormeloxifene: The Perfect Alternative for the First-line Management of Abnormal Uterine Bleeding

Abstract

Aim:The aim of this work was to study the role of Ormeloxifene in the management of abnormal uterine bleeding (AUB). Methods: Fifty-one patients with heavy menstrual bleeding with ages between 18 and 50 years were included in the study. The women with post-menopausal bleeding, fibroids, uterus size of more than 8 weeks, polycystic ovarian syndrome (PCOS), and ovarian cysts were excluded. Ormeloxifene (60 mg) twice a week for 12 weeks and then once a week for the next 12 weeks was given to every patient in the study group. The outcome was assessed by the pictorial blood assessment chart (PBAC) score, hemoglobin (HB) level, and endometrial thickness. Results: About 88.24% of patients responded well to treatment as depicted by a significant reduction in the PBAC score to a level <100. The mean PBAC score decreased linearly from 354 to 40 at the end of 24 weeks of treatment. Mean endometrial thickness reduced from 8.25 to 6.01. The mean level of hemoglobin level increased from 11.41 to 11.86. P-value of all the parameters were <0.05 and hence statistically significant. Conclusion: Ormeloxifene can be used as a first-line drug for the management of AUB.